HDAC9 and glioblastoma: Suberoylanilide hydroxamic acid (SAHA), a HDAC inhibitor, has been shown to possess cytotoxicity in various cancer cell-types such as T-cell lymphoma [10], breast cancer [11], prostate cancer [12], and glioblastoma cells [10].